ABSTRACT
INTRODUCTION
Lung cancer is the leading cause of cancer deaths worldwide. Non-small cell lung cancer (NSCLC) accounts for approximately 80% of lung cancers, and the majority are already unresectable and metastatic upon their initial diagnosis. Cytotoxic chemotherapies such as platinumbased regimens were once the primary therapeutic option for metastatic NSCLC, but their advancement has reached a plateau. Molecular-targeted therapies have been recently developed, and they have provided a remarkable benefit to patients harboring specific genetic alterations such as epidermal growth factor receptor (EGFR) gene mutations or anaplastic lymphoma kinase (ALK) gene fusions [1] [2] [3] . Efficacies of up-front EGFR-and ALKtyrosine kinase inhibitors (TKIs) have been established for patients harboring these genetic alterations in prospective randomized phase III trials comparing platinum doublets, and the median progression-free survivals (PFSs) are approximately 12 months [4] [5] . Despite an initial dramatic response, most patients receiving these TKIs finally acquire resistance. Therefore, further salvage therapeutic options are necessary after failure of these molecular-targeted therapies.
On the other hand, current advancement of immunotherapies is evolving. Among them, anti-programmed death-1 (PD-1)/PD-ligand 1 (PD-L1) antibodies have demonstrated their splendid efficacies in pretreated NSCLC. Anti-PD-1/PD-L1 antibodies, such as nivolumab, pembrolizumab, and atezolizumab have shown survival benefit in pretreated patients with NSCLC after failure of platinum doublet chemotherapies, in randomized phase III trials compared to docetaxel monotherapy [6] [7] [8] [9] . Based on results of these trials, anti-PD-1/PD-L1 antibody monotherapies have become standard treatments for pretreated NSCLC.
In cases responding to such immunotherapies, durable response is expected over 1-2 years, much longer than common cytotoxic agents [6] [7] [8] [9] . Unfortunately, the response rate and PFS of these immunotherapies are generally 10-20% and 2-3 months, respectively, and relatively many patients obtain no response and experience early progression. Notably, several studies demonstrated a possible poorer efficacy of anti-PD-1 antibodies for patients with EGFR mutations [7] [8] [9] . However, such immunotherapies are not always ineffective even in EGFR-mutant NSCLC. Practical predictive markers are necessary to select patients who benefit from anti-PD-1/ PD-L1 antibody immunotherapies.
Several predictive markers for anti-PD-1/PD-L1 antibodies have been developed [10] . Among them, PD-L1 expression is the most widely investigated predictive marker for many types of cancers. Some studies for NSCLC have demonstrated correlations between PD-L1 expression and efficacies of anti-PD-1/PD-L1 antibodies [7] [8] [9] 11] . One of them has shown that nivolumab was associated with longer overall survival, longer PFS, and higher objective response rates than docetaxel in pretreated NSCLC at the prespecified PD-L1 expression levels of ≥1%, ≥5%, and ≥10% [7] .
We thus hypothesized lower PD-L1 expression in EGFR-mutant NSCLC samples than in EGFR-wild type. The aim of this study was to investigate correlation between PD-L1 expression and EGFR mutation status in pretreated NSCLC.
RESULTS

Sample and patient profile
Flow chart of final investigated samples and patients is shown in Figure 1 
Comparison of PD-L1 expression between EGFR-mutant and wild-type samples
Median H-score in EGFR-mutant samples (n=65) was 3 (range, 0-150), whereas EGFR-wild-type (n=31) was 8 (range, 0-134) (Wilcoxon, p=0.0075) ( Figure  2 ). Using H-scores ≥1, ≥5, ≥10, ≥25, and ≥50 cut-offs, incidence of PD-L1+ in EGFR-mutant vs. EGFR-wild-type samples were 85% (55/65) vs. 94% (29/31) (p=0.2159), 42% (27/65) vs. 74% (23/31) (p=0.0027), 22% (14/65) vs. 48% (15/31) (p=0.0074), 5% (3/65) vs. 19% (6/31) (p=0.0205), and 3% (2/65) vs. 10% (3/31) (p=0.1735), respectively ( Figure 3 ). Figure 4 shows PD-L1 expression of representative samples: A, EGFRmutant (Del-19) (H-score: 0); B, EGFR-mutant (L858R) (H-score: 10); and C, EGFR wild-type (H-score: 134).
Patient-oriented univariate and multivariate analyses for strong PD-L1+
Patient-oriented (n=77) univariate and multivariate analyses for strong PD-L1+ were performed at H-score ≥10 cut-off. In patients receiving multiple rebiopsy, first rebiopsy results were adopted in these analyses. Univariate analysis was performed on: age (<70 vs. 70≤); gender (male vs. female); smoking status (never vs. former vs. current); histology (adeno vs. non-adeno); EGFR mutation status (mutant vs. wild-type); radiation before rebiopsy for sampled tissue (irradiated vs. non-irradiated); cytotoxic chemotherapy before rebiopsy (received vs. none) rebiopsy site (lung vs. extra-lung); and age of sample (<12 months vs. 12 months≤). EGFR-TKIs before rebiopsy (prescribed vs. none) was eliminated because of strong confounding to EGFR mutation status. Univariate analysis found EGFR mutation status (p=0.0490) and age of sample (p=0.0226) as significant factors for strong PD-L1+ (Table 2) . Results of multivariate analysis using the logistic regression model are shown in Table 3 . We identified EGFR status as the only significant factor for strong PD-L1+ (odds ratio, 2.99; 95% confidence interval, 1.34-7.56; and p=0.0121).
PD-L1 expression in multiple rebiopsied cases
Eleven (14%) patients underwent multiple rebiopsies. H-scores of PD-L1 expression varied in all 11 cases receiving multiple rebiopsies (Table 4) . PD-L1 expression increased in 7 (64%) patients, whereas decreased in 6 (55%) patients. Categories of positivity: negative (H-score=0); weak+ (1≤ H-score <5); moderate+ (5≤ H-score <10): strong+ (10≤ H-score) migrated in 10 (91%) of 11 patients.
DISCUSSION
We herein demonstrate a lower PD-L1 expression in EGFR-mutant NSCLC samples than in EGFR wildtype samples. Using H-scores ≥1, ≥5, and ≥10 cut-offs, incidences of PD-L1+ in EGFR-mutant samples was also less than in wild-type samples. These results suggest poorer efficacy of anti-PD-1/PD-L1 immunotherapies in EGFR-mutant than in wild-type. Gainor et al have reported that NSCLC harboring EGFR mutations or ALK-fusions were associated with low overall response rate to PD-1/ PD-L1 inhibitors [12] . They have also showed lower PD-L1 expression of tissues in these driver oncogene-positive populations than in EGFR/ALK wild-type population. Our IHC results and their data both support subgroup analyses of clinical studies which showed poorer efficacy of anti-PD-1/PD-L1 immunotherapies in EGFR-mutant subgroup [7] [8] [9] .
Meanwhile, some studies using surgical samples of chemo-naïve NSCLC have shown lower PD-L1 expression in EGFR-mutant NSCLC than in EGFR wild-type, as we have demonstrated [13, 14] . Others have exhibited higher PD-L1 expression in EGFR-mutant NSCLC than in EGFR wild-type [15] [16] [17] [18] . This issue is still controversial and debatable. Notably, our study and several clinical studies have found a possible temporal heterogeneity of PD-L1 expression by therapeutic interventions, especially EGFR-TKIs [12, 19] . Preclinical studies have also shown that PD-L1 expression was reduced by EGFRTKIs in NSCLC cell lines harboring EGFR activating mutations [20, 21] . Not chemo-naïve surgical samples, but pretreated histological samples (EGFR-mutant: after EGFR-TKI therapies) are more desirable for studies to investigate PD-L1 expression. Moreover, anti-PD-1 antibodies, nivolumab and pembrolizumab are approved only in pretreated patients with EGFR-mutant NSCLC. To properly investigate this issue, it is preferable to examine pretreated samples for best reflection of study results into clinical practice. Thus, our study focused on histological samples of pretreated NSCLC patients, which is more clinically valuable than studies using chemo-naïve surgical samples.
Our multivariate analysis identified EGFR status as the only significant factor for strong PD-L1+. Based on results of pivotal studies regarding nivolumab, PD-L1 expression was associated with clinical efficacies in nonsquamous NSCLC population [7] . Although ascertaining PD-L1 expression could be beneficial for non-squamous NSCLC, PD-L1 IHC using 28-8 antibody is uncommon in current clinical practice. We can only utilize clinically available predictive markers. Smoking history and histology might have a predictive value [10, 13, 22] , but our multivariate analysis did not reveal a statistical significance. A meta-analysis indicated PD-L1 expression was not associated with common clinicopathological characteristics such as smoking history and histology, except tumor differentiation [23] . Clinical practice demands a routine EGFR mutational analysis, which is performed in most cases. Therefore, EGFR status could be useful as a predictive marker of anti-PD-1/PD-L1 antibody therapies in pretreated patients with NSCLC.
Age of sample was identified as a significant factor for strong PD-L1+ in our univariate analysis, but multivariate analysis failed to confirm this result. Older samples revealed lesser prevalence of strong PD-L1+. This result implies a possible underestimation of PD-L1 expression in older samples. Several studies suggested that tissue processing and storage could alter the ability to detect PD-L1 in tumor samples [24] . The decreased prevalence may be caused by PD-L1 protein denaturation with formalin fixation and a loss in PD-L1 antigenicity.
Age of sample could result in loss of detection of PD-L1 [25] . Based on these studies and our results, rebiopsied fresh samples may be better for PD-L1 IHC.
Issues of PD-L1 IHC contain not only tissue processing and storage but also interpretation of the test by pathologists. Reproducibility is another issue in PD-L1 IHC scoring. We adopted a digital pathological systematic procedure (Aperio). This system can digitally evaluate PD-L1 IHC scores, and demonstrated highly similar IHC staining results to visual evaluation by a pathologist [26] . Our pathologists also confirmed PD-L1 IHC score of each sample, and PD-L1 H-scores were similar between digital procedure and pathologists.
Our study includes several limitations. First is the selection of antibody for PD-L1 IHC. Our study adopted the 28-8 PD-L1 antibody. Four anti PD-L1 antibodies (28-8, 22c3 , SP142, and SP263) are clinically used for PD-L1 IHC, but PD-L1 IHC is not globally standardized [27] . Each IHC antibody has been developed simultaneously with each anti-PD-1/PD-L1 therapeutic antibody (nivolumab, pembrolizumab, atezolizumab, and durvalumab). In order to translate basic data for clinical practice, one of these four antibodies for PD-L1 IHC should be used in clinical studies to investigate PD-L1 expression. At present, nivolumab is one of the most widely used immunotherapies in Japan, and thus the 28-8 antibody is an optimal antibody choice for PD-L1 IHC. Second is our cut-offs for PD-L1 positivity. We adopted H-score to evaluate both percentage and intensity, and defined H-scores ≥1 as PD-L1+, scores ≥5 as moderate PD-L1+, and scores ≥10 as strong PD-L1+, largely equivalent to PD-L1 expression ≥1%, ≥5%, and ≥10% cut-offs. Pivotal studies using nivolumab determined PD-L1 expression ≥1%, ≥5%, and ≥10% as their cut-offs [6, 7] , and a study for non-squamous NSCLC has demonstrated significant correlation between PD-L1+ status and clinical efficacy of nivolumab [7] . Although optimal cut-off for PD-L1 positivity is yet to be determined, we are sure that our adopted cut-off is appropriate. In conclusion, our study has demonstrated a significantly lower PD-L1 expression in EGFR-mutant NSCLC samples than in EGFR wild-type samples. As several studies have shown [7] [8] [9] , efficacies of anti-PD-1/ PD-L1 immunotherapies in EGFR-mutant population appear to be poorer than those in EGFR wild-type population. Priority of anti-PD-1/PD-L1 immunotherapies might be lower in EGFR-mutant population than in EGFR wild-type population. Our multiple rebiopsied cases suggested PD-L1 expression dynamism. Age of sample could affect PD-L1 expression, and rebiopsied fresh samples may be better for PD-L1 IHC. Further studies are warranted to investigate association between PD-L1 expression and EGFR mutation status. 
MATERIALS AND METHODS
Samples and patients
We retrospectively screened electronic medical records of patients with NSCLC in our institute. Two sampling cohorts were adopted to collect histological samples in pretreated patients with NSCLC. The first was histological rebiopsied samples after several chemotherapies, regardless of driver oncogene alterations such as EGFR/ALK. The second was surgical tissue samples after neoadjuvant chemoradiation therapy. After exclusion of samples with ALK-fusion, we examined whether each sample contained sufficient cancer cells to perform PD-L1 immunohistochemistry (IHC). After confirmation of cancer cell sufficiency, PD-L1 IHC was carried out. Never smoker was defined as patients who had never smoked in their lifetime. Current smoker was categorized as those who had smoked within 1 year of the diagnosis. The rest were regarded as former smoker. The study was approved by the institutional review board, and complied with the Declaration of Helsinki.
EGFR mutational analysis
We isolated tumor DNA from each specimen, and analyzed EGFR mutations using highly sensitive assays: the peptide nucleic acid-locked nucleic acid PCR clamp method [28] or the cycleave method [29] .
PD-L1 immunohistochemistry
Paraffin-embedded tumor tissue was sectioned at a thickness of 4 μm, and the sections were then pasted on coated glass slides for PD-L1 IHC. PD-L1 IHC was performed using the 28-8 antibody for tumor cell membrane staining. Slides were stained with Dako Autostainer Link48. Antigen retrieval was performed in Target Retrieval Solution Low pH. The primary antibody of PD-L1 (clone: 28-8) was diluted at 1:600, and incubated for 45 min at room temperature. The antibody was detected with Rabbit (LINKER) and EnVision FLEX/ HRP. Digital image was captured using Aperio Scanscope AT Turbo slide scanner (Leica Biosystems, Vista, CA, USA) under 20x objective magnification. Scoring of PD-L1 was performed using digital image analysis software, namely Aperio membrane v9 and Aperio Genie Classifier. Score of PD-L1 was represented as H-score to evaluate both percentage and intensity. Semiquantitative H-score (maximum value of 300 corresponding to 100% of tumor cells positive for PD-L1 with an overall staining intensity score of 3) was determined by multiplying the percentage of stained cells by an intensity score (0, absent; 1,weak; 2, moderate; and 3, strong). Our pathologists also confirmed PD-L1 IHC score, and no significant difference was found in PD-L1 scores between digital procedure and pathologists. We defined H-scores ≥1 as PD-L1+, scores ≥5 as moderate PD-L1+, and scores ≥10 as strong PD-L1+. 
Statistical analyses
To compare H-scores between EGFR-mutant and wild-type samples, we used the Wilcoxon rank sum test. Chi-square test was done to compare the incidence of PD-L1+. Multivariate analysis for strong PD-L1+ was performed using the logistic regression model. Final investigating variables were selected by backward elimination method. A P-value less than 0.05 was considered significant. The statistical analyses were performed using JMP 12 (SAS Institute, Inc., Cary, NC, USA).
